Abivax's oral ulcerative colitis drug obefazimod surpassed expectations in Phase III trials, prompting a Nasdaq offering that was oversubscribed fivefold and raised nearly $750 million. CEO Marc de Garidel called the drug a potential blockbuster and highlighted plans to invest extensively in clinical development for ulcerative colitis and Crohn’s disease. Abivax saw its shares rally dramatically in both U.S. and European markets, reflecting strong investor confidence in the candidate's commercial potential.